Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System Documento uri icon

  •  
  • Visão geral
  •  
  • Pesquisas
  •  
  • Identidade
  •  
  • Informação adicional documento
  •  
  • Outro
  •  
  • Ver todos
  •  

tipo

  • journal article

data de publicação

  • 2020-01-01